Everest Medicines MT1013 Deal Expands Renal Pipeline As Shares Lag Targets

• Everest Medicines (SEHK:1952) has signed an exclusive license agreement to commercialize MT1013 for secondary hyperparathyroidism in China and the broader Asia Pacific region.
• MT1013 is entering Phase III trials, with development expenses covered by Everest Medicines' partner under the deal.
• The agreement expands the company’s renal pipeline and commercial portfolio, targeting unmet medical needs in kidney related complications.

Everest Medicines, trading at HK$38.86, has seen mixed share performance, with a 2.4% decline over the past week and a 2.7% decline over the past 30 days, while year to date returns stand at 2.5%. Over a 3 year period the stock shows a 69.3% gain, set against a 5.9% decline over the past year and a 60.1% decline over 5 years, highlighting how sentiment around the name has shifted at different points in time.

For investors watching SEHK:1952, the MT1013 license brings a fresh asset into a focused renal portfolio, with clinical data suggesting efficacy and safety benefits relative to current therapies. With Phase III costs covered by the partner, the agreement could influence how investors think about Everest Medicines’ capital needs and exposure to the secondary hyperparathyroidism treatment area.

Stay updated on the most important news stories for Everest Medicines by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Everest Medicines.

How Everest Medicines stacks up against its biggest competitors

Quick Assessment

• ✅ Price vs Analyst Target: At HK$38.86 versus a HK$63.21 analyst target, the price is about 39% below consensus.
• ✅ Simply Wall St Valuation: Shares are flagged as trading 54.5% below the platform's estimated fair value.
• ❌ Recent Momentum: The stock has a 2.7% decline over the last 30 days.

Check out Simply Wall St's in depth valuation analysis for Everest Medicines.

Key Considerations

• 📊 The MT1013 license adds another renal asset that could help support the company’s focus on kidney related complications in China and Asia Pacific.
• 📊 Keep an eye on Phase III progress for MT1013, revenue trends from the broader portfolio, and how the HK$38.86 price tracks against the HK$63.21 target.
• ⚠️ Execution risk around late stage clinical trials and eventual commercialization of MT1013 is central to whether this agreement creates long term value.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Everest Medicines analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com